These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8507875)

  • 21. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
    Kantarjian HM; Smith T; Estey E; Polyzos A; O'Brien S; Pierce S; Beran M; Feldman E; Keating MJ
    Am J Med; 1992 Dec; 93(6):599-604. PubMed ID: 1466355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
    Brenning G; Wibell L; Bergström R
    Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
    Scarffe JH; Anderson H; Palmer MK; Crowther D
    Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma.
    Rajkumar SV; Fonseca R; Dewald GW; Therneau TM; Lacy MQ; Kyle RA; Greipp PR; Gertz MA
    Cancer Genet Cytogenet; 1999 Aug; 113(1):73-7. PubMed ID: 10459351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment serum beta 2-microglobulin in multiple myeloma.
    Brenning G; Simonsson B; Källander C; Ahre A
    Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
    Kraj M; Maj S; Pogłód R; Rostkowska J
    Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
    Itälä M; Pelliniemi TT; Remes K
    Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.
    Sarı M; Sarı S; Nalçacı M
    Turk J Haematol; 2017 Jun; 34(2):131-136. PubMed ID: 27795224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
    Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
    Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma.
    Tienhaara A; Remes K; Pelliniemi TT
    Br J Haematol; 1991 Mar; 77(3):335-8. PubMed ID: 2012758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-reactive protein (CRP) levels do not reflect disease status in patients with multiple myeloma.
    Brown RD; Snowdon L; Uhr E; Gibson J; Joshua D
    Leuk Lymphoma; 1993 Apr; 9(6):509-12. PubMed ID: 8339052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma.
    Bartl R; Frisch B; Diem H; Mündel M; Nagel D; Lamerz R; Fateh-Moghadam A
    Cancer; 1991 Nov; 68(10):2241-50. PubMed ID: 1913461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis?
    Boccadoro M; Gallone G; Frieri R; Pileri A; Bataille R; Klein B
    Blood; 1993 Dec; 82(11):3507-8. PubMed ID: 8241520
    [No Abstract]   [Full Text] [Related]  

  • 39. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
    Lehtinen T
    Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.